Kissei PharmaceuticalKISSEI PHARMACEUTICAL CO.,LTD.4547東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

Kissei Pharmaceutical FY ending Mar 2020 results

About 81% of Kissei Pharmaceutical's sales come from Pharmaceutical products, with Information Service and Construction contracting making up much of the rest.

Out of every ¥100 of sales, about ¥3 is left as operating profit.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Kissei Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2020

Cost of sales: ¥45
SG&A: ¥52
Operating profit: ¥3
Net profit kept: ¥4

Margin funnel (derived from reported values)Gross margin 55.2% → Operating margin 2.9% → Net margin 4.5%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Pharmaceutical products¥51.3B
81%
Op. margin 1.8%Industry: Pharmaceuticals
Information Service¥6.63B
10%
Op. margin 8.2%Industry: IT Services & System Integration
Construction contracting¥3.61B
6%
Op. margin 7.6%
Trading business¥1.68B
3%
Op. margin 1.7%Industry: Specialty Trading & Wholesale

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第79期(2023/04/01－2024/03/31)
ID S100TRIA2024-06-25Open
EDINET (FSA Japan)
訂正有価証券報告書－第77期(令和3年4月1日－令和4年3月31日)
ID S100OOE82022-07-06Open
EDINET (FSA Japan)
有価証券報告書－第76期(令和2年4月1日－令和3年3月31日)
ID S100LO0H2021-06-24Open

Extracted from XBRL: 48 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image